FCGR2A and neoplasm: While tumor-bearing mouse model is widely adopted to assess the anti-tumor efficacy of therapeutic antibodies, it is not the best choice for assessment of human FcγR-enhanced antibodies since human and mouse FcγRs own different expression pattern and divergent binding affinity to human IgG 42, 43.